Castle Biosciences (CSTL) Competitors $23.46 +1.64 (+7.52%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$24.16 +0.70 (+2.99%) As of 09/18/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. VCYT, CELC, LFST, ADUS, PGNY, ARDT, NHC, AVAH, VRDN, and PACSShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Veracyte (VCYT), Celcuity (CELC), LifeStance Health Group (LFST), Addus HomeCare (ADUS), Progyny (PGNY), Ardent Health (ARDT), National HealthCare (NHC), Aveanna Healthcare (AVAH), Viridian Therapeutics (VRDN), and PACS Group (PACS). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Its Competitors Veracyte Celcuity LifeStance Health Group Addus HomeCare Progyny Ardent Health National HealthCare Aveanna Healthcare Viridian Therapeutics PACS Group Castle Biosciences (NASDAQ:CSTL) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has more risk and volatility, CSTL or VCYT? Castle Biosciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Is CSTL or VCYT more profitable? Veracyte has a net margin of 5.50% compared to Castle Biosciences' net margin of -2.73%. Veracyte's return on equity of 6.07% beat Castle Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Castle Biosciences-2.73% 2.37% 2.03% Veracyte 5.50%6.07%5.53% Do insiders & institutionals hold more shares of CSTL or VCYT? 92.6% of Castle Biosciences shares are owned by institutional investors. 6.5% of Castle Biosciences shares are owned by company insiders. Comparatively, 1.4% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, CSTL or VCYT? Veracyte has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCastle Biosciences$346.27M1.97$18.25M-$0.35-67.03Veracyte$479.13M5.46$24.14M$0.33100.70 Does the media favor CSTL or VCYT? In the previous week, Castle Biosciences had 7 more articles in the media than Veracyte. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for Veracyte. Veracyte's average media sentiment score of 1.68 beat Castle Biosciences' score of 1.50 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Veracyte 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate CSTL or VCYT? Castle Biosciences currently has a consensus target price of $37.00, indicating a potential upside of 57.72%. Veracyte has a consensus target price of $40.90, indicating a potential upside of 23.08%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Castle Biosciences is more favorable than Veracyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Castle Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 SummaryVeracyte beats Castle Biosciences on 10 of the 15 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$632.95M$3.12B$5.78B$10.26BDividend YieldN/A2.37%5.74%4.64%P/E Ratio-67.0321.3676.7126.98Price / Sales1.97423.19512.57164.86Price / Cash22.1845.3237.1760.63Price / Book1.449.6913.666.37Net Income$18.25M-$52.92M$3.29B$271.46M7 Day Performance9.52%2.19%1.55%2.53%1 Month Performance17.89%8.96%6.81%9.42%1 Year Performance-23.16%10.84%79.53%30.16% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences2.5201 of 5 stars$23.46+7.5%$37.00+57.7%-22.7%$632.95M$346.27M-67.03540Positive NewsVCYTVeracyte3.8065 of 5 stars$31.87+3.2%$40.90+28.3%-1.6%$2.43B$479.13M96.58790Positive NewsCELCCelcuity1.2712 of 5 stars$55.07+0.3%$56.50+2.6%+266.6%$2.33BN/A-15.9640LFSTLifeStance Health Group3.0878 of 5 stars$5.18-1.0%$8.50+64.1%-20.3%$2.03B$1.25B-103.6010,218ADUSAddus HomeCare4.9901 of 5 stars$109.27-0.9%$138.89+27.1%-17.1%$2.03B$1.15B24.1249,703Positive NewsPGNYProgyny3.7286 of 5 stars$22.13-1.7%$25.30+14.3%-7.9%$1.94B$1.17B37.51310Positive NewsARDTArdent Health3.4445 of 5 stars$12.65-3.3%$19.33+52.8%-22.1%$1.87B$5.97B6.9924,900Positive NewsNHCNational HealthCareN/A$116.17+1.0%N/A-3.6%$1.80B$1.46B14.5612,400AVAHAveanna Healthcare1.2542 of 5 stars$8.39-0.6%$7.50-10.6%+59.9%$1.76B$2.02B104.8833,500Trending NewsAnalyst UpgradeVRDNViridian Therapeutics2.077 of 5 stars$18.01-4.6%$37.78+109.8%-6.8%$1.54B$300K-4.7050PACSPACS Group3.1631 of 5 stars$10.41+6.8%$31.00+197.8%-70.6%$1.49B$3.11B0.0032,433Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Veracyte Alternatives Celcuity Alternatives LifeStance Health Group Alternatives Addus HomeCare Alternatives Progyny Alternatives Ardent Health Alternatives National HealthCare Alternatives Aveanna Healthcare Alternatives Viridian Therapeutics Alternatives PACS Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
